Every 40 seconds, someone in the United States has a stroke. For survivors of the most common type of stroke, called an ischemic stroke, only about 5 percent fully recover.
Cell BioEngines, Inc. (“Cell BioEngines” or the “Company”), a clinical-stage biotechnology company developing a universal ‘plug-and-play’ allogeneic stem cell therapy platform and a portfolio of ...
Researchers at Gladstone Institutes and SanBio demonstrated that a stem cell therapy, effective even a month after stroke, restored brain function in rats by reversing hyperexcitability and enhancing ...